LGPXE
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π Esg
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
0
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Little Green Pharma Ltd - Ent To Shares In Reset Mind Sciences Limited
π Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in LGPXE
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in LGPXE
N/A
LGPXE investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in LGPXE also invest in...
Want more shares? Try these...
Little Green Pharma Ltd. produces medicinal cannabis products for sale to Australian patients. The company is headquartered in Perth, Western Australia. The company went IPO on 2020-02-20. Its principal activities include the cultivation of medicinal cannabis, procurement of raw materials and production of medicinal cannabis medicines; the supply of medicinal cannabis products into Australia and Europe; the supply of medicinal cannabis products for observational and clinical studies and research and development of new medicinal cannabis products, and the development of a psychedelics business including sponsoring a clinical trial into the treatment of refractory depression with psilocybin assisted therapy, construction of a psilocybin mushroom cultivation facility, and establishment of a psychedelic treatment clinic. The company has two global production sites for the manufacture of its own-branded and white-label ranges medicinal cannabis products.
π Performance (5Yr p.a)
-13.17%
π Share price
$0.14 AUD
π¦ LOGISTICS